PharmaCyte BiotechPMCB -0.30%32 Quick Ratio is 12.33 as of Jan. 2026, which is 147% above its 10-year median of 5.00. GuruFocus rates PMCB with a GF Score™ of 32/100. The stock has 2 warning signs investors should review. Among 1,417 Biotechnology companies, PharmaCyte Biotech ranks better than 83.2% on this metric.
PharmaCyte Biotech has a quick ratio of 12.33. It generally indicates good short-term financial strength.
The historical rank and industry rank for PharmaCyte Biotech's Quick Ratio or its related term are showing as below:
PMCB'
s Quick Ratio Range Over the Past 10 Years
Min: 0.21 Med: 5 Max: 468.71
Current: 12.33
During the past 13 years, PharmaCyte Biotech's highest Quick Ratio was 468.71. The lowest was 0.21. And the median was 5.00.
PMCB's Quick Ratio is ranked better than 83.2% of 1417
companies
in the Biotechnology industry
Industry Median: 3.6
vs PMCB: 12.33
PharmaCyte Biotech (NAS:PMCB) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
PharmaCyte Biotech Quick Ratio Related Terms
PharmaCyte Biotech Quick Ratio Historical Data
* Premium members only.
The historical data trend for PharmaCyte Biotech's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, PharmaCyte Biotech's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PharmaCyte Biotech Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, PharmaCyte Biotech's Quick Ratio distribution charts can be found below:
* The bar in red indicates where PharmaCyte Biotech's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
PharmaCyte Biotech's Quick Ratio for the fiscal year that ended in Apr. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PharmaCyte Biotech (PMCB) has a Quick Ratio of 12.33 as of Jan. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on PharmaCyte Biotech and its competitors. This is 147% above median its historical median of 5.00. Over the past decade, PharmaCyte Biotech's Quick Ratio has ranged from 0.21 to 468.71. According to the industry distribution chart, PharmaCyte Biotech ranks #238 out of 1417 companies in the Biotechnology industry, placing it in the top 16.8%.
Is PharmaCyte Biotech's Quick Ratio too high?
PharmaCyte Biotech's current Quick Ratio of 12.33 is 147% above median its 10-year median of 5.00. Over the past 10 years, this metric has ranged from a low of 0.21 to a high of 468.71. The Biotechnology industry median Quick Ratio is 3.60. PharmaCyte Biotech's value of 12.33 is 242.5% above this industry median. Based on the distribution chart, PharmaCyte Biotech ranks #238 out of 1417 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, PharmaCyte Biotech has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does PharmaCyte Biotech's Quick Ratio compare to IMNN and ACXP?
According to the Biotechnology industry distribution chart, PharmaCyte Biotech ranks #238 out of 1417 companies for Quick Ratio. This places PharmaCyte Biotech in the top 17% of its industry — outperforming the majority of peers. The industry median Quick Ratio is 3.60. PharmaCyte Biotech's value of 12.33 is 242.5% above this benchmark. Historically, PharmaCyte Biotech's own Quick Ratio has ranged from 0.21 to 468.71 over the past decade. While the company's 10-year median is 5.00 vs. the industry median of 3.60, PharmaCyte Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,417 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PharmaCyte Biotech's current Quick Ratio of 12.33 is 242.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on PharmaCyte Biotech and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PharmaCyte Biotech's current Quick Ratio is 12.33, which is 147% above median its own 10-year median of 5.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PharmaCyte Biotech stock overvalued right now?
PharmaCyte Biotech (PMCB) has a current Quick Ratio of 12.33. The current Quick Ratio is 12.33, which is 147% above median its 10-year median of 5.00 and 242.5% above the Biotechnology industry median of 3.60. PharmaCyte Biotech's overall GF Score™ is 32/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For PharmaCyte Biotech (PMCB), the current Quick Ratio is 12.33 as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.
32GF Score
Get the complete analysis for PMCB
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PMCB has been successfully added to your 
